Did you mean 3210 40 8?
Displaying drugs 451 - 475 of 2344 in total
Cytarabine
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale,...
Approved
Investigational
Matched Products: … CYTARABINE INJ 40 MG FLAKON, 10 ADET ... ALEXAN 40 MG/2 ML IV/SC INTRATEKAL ENJEKSİYON/İNFÜZYON İÇİN ÇÖZELTİ İÇEREN FLAKON, 10 ADET ... ALEXAN 40 MG/2 ML IV/SC INTRATEKAL ENJEKSİYON/İNFÜZYON İÇİN ÇÖZELTİ İÇEREN FLAKON, 30 ADET …
Betamethasone
Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity.
Approved
Vet approved
Matched Products: … XORSONE 1:8 cream ... BETAMETASONA 8 MG/ 2 ML ... BETAMETASONA INYECTABLE X 8 MG/ 2 ML …
Povidone-iodine
Povidone-iodine is a stable chemical complex of polyvinylpyrrolidone (povidone, PVP) and elemental iodine. It contains from 9.0% to 12.0% available iodine, calculated on a dry basis. This unique complex was discovered in 1955 at the Industrial Toxicology Laboratories in Philadelphia by H. A. Shelanski and M. V. Shelanski. During in...
Approved
Matched Mixtures name: … Dyural 40 Kit ... Dyural 40 Kit …
Matched Products: … RECURAT®8% ESPUMA ... IODOPLUS 8% ESPUMA ... FISOHEX 8 % ESPUMA …
Matched Products: … RECURAT®8% ESPUMA ... IODOPLUS 8% ESPUMA ... FISOHEX 8 % ESPUMA …
Cabozantinib
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal...
Approved
Investigational
Matched Products: … CABOMETYX 40 MG FİLM KAPLI TABLET, 30 ADET …
Duloxetine
Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a...
Approved
Matched Products: … YENTREVE 40 MG ... DULOXETIN HEU 40 KMR ... DULOXETIN-NEURAX 40 MG …
Levocetirizine
Levocetirizine is a selective histamine H1 antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of cetirizine. Levocetirizine has greater affinity for the histamine H1 receptor than cetirizine. Levocetirizine was granted FDA approval in 1995.
Approved
Matched Products: … XYZAL 5 MG FİLM TABLET, 40 ADET ... LEVOSETIL 5 MG FILM TABLET ,40 TB ... RINIREX 5 MG FILM KAPLI TABLET ,40 TABLET …
Pasireotide
Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Approved
Matched Products: … SIGNIFOR® LAR 40 MG ... SIGNIFOR LAR (40 MG POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION) …
Ephedrine
Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with pseudoephedrine. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepinephrine from sympathetic neurons,...
Approved
Matched Mixtures name: … HEMORALGINE 40 GR POMAD …
Matched Products: … Ephedrine HCl 8 mg …
Matched Products: … Ephedrine HCl 8 mg …
Siltuximab
Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment...
Approved
Investigational
Matched Description: … (HHV-8) negative. ... Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 …
BCG vaccine
BCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.
Approved
Investigational
Matched Products: … SII-ONCO-BCG (Powder for Intravesical Instillation) BCG Live USP. 1 vial of 40 mg/ml …
Nicardipine
A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [PubChem]
Approved
Investigational
Matched Products: … CARDIBLOC-SR CAPSULE 40 mg …
Oxaliplatin
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride...
Approved
Investigational
Matched Products: … OXALIPLATINO 200MG/ 40 ML SOLUCION INYECTABLE ... PLATOXATİN 200 MG/40 ML I.V. İNFÜZYONLUK ÇÖZELTİ, 1 ADET ... OXALİPLATİN KABİ 200 MG/ 40 ML IV İNFÜZYONLUK KONSANTRE ÇÖZELTİ, 1 ADET …
Tilbroquinol
Tilbroquinol was approved in France, Morocco, and Saudi Arabia but it has been withdrawn in France and Saudi Arabia markets mainly due to its hepatotoxicity risk outweighing the drug benefit . In Morocco, the drug has been limited to use in the treatment of intestinal amoebiasis.
Approved
Matched Iupac: … 7-bromo-5-methylquinolin-8-ol …
Avobenzone
Avobenzone is dibenzoyl methane derivative. It is oil soluble ingredient. Avobenzone has the ability to absorb ultraviolet light over wider range of wavelengths. It is included in many commercially available sunscreens which are used as wide spectrum sunscreens. Avobenzone is very sensitive to light, to increase its stability and duration...
Approved
Investigational
Matched Mixtures name: … Meijer SPF 8 ... Meijer SPF 8 ... Panama Jack SPF 8 …
Dextrose, unspecified form
Glucose is a simple sugar (monosaccharide) generated during phosynthesis involving water, carbon and sunlight in plants. It is produced in humans via hepatic gluconeogenesis and breakdown of polymeric glucose forms (glycogenolysis). It circulates in human circulation as blood glucose and acts as an essential energy source for many organisms through...
Approved
Vet approved
Matched Mixtures name: … Physioneal 40 Glucose 1.36% ... Physioneal 40 Glucose 2.27% ... Physioneal 40 Glucose 3.86% …
Matched Products: … 40% Dextrose Injection USP ... 40% Dextrose Injection, USP ... Monoject Insulin Reaction Gel 40% …
Matched Products: … 40% Dextrose Injection USP ... 40% Dextrose Injection, USP ... Monoject Insulin Reaction Gel 40% …
Spesolimab
Spesolimab is an interleukin-36 (IL-36) receptor antagonist. It is a humanized monoclonal immunoglobulin G1 antibody that was produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. The biosimilar of the drug, spesolimab-sbzo, was first approved by the FDA in September 2022 to treat generalized pustular psoriasis flares. Spesolimab...
Approved
Investigational
Brimonidine
Brimonidine is an alpha-adrenergic agonist and 2-imidazoline derivative that was first introduced in 1996. It is considered to be a third generation alpha-2 aadrenergic receptor agonist, since it displays preferential binding at alpha-2 adrenoceptors over alpha-1 receptors. Brimonidine displays a higher selectivity toward the alpha-2 adrenergic receptors than clonidine or...
Approved
Matched Products: … Brimonidine Tartrate 0.25% / Potassium Azeloyl Diglycinate 8% …
Ancrod
Ancrod, marketed as Viprinex, is a defibrinogenating agent derived from Malayan pit viper venom. The defribrinogenation of blood results in an anticoagulant effect. Currently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. In January 2005, the U.S....
Approved
Investigational
Pegvaliase
Pegvaliase is a recombinant phenylalanine ammonia lyase (PAL) enzyme derived from Anabaena variabilis that converts phenylalanine to ammonia and trans-cinnamic acid . Both the U.S. Food and Drug Administration and European Medicines Agency approved pegvaliase-pqpz in May 2018 for the treatment of adult patients with phenylketonuria (PKU). Phenylketonuria is a...
Approved
Investigational
Frovatriptan
Frovatriptan is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head.
Approved
Investigational
Chlorpromazine
The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
Approved
Investigational
Vet approved
Matched Products: … Chlorpromanyl 40 Drops Syr 44.5mg/ml …
Spiramycin
Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii and Cryptosporidium.
Spiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in...
Approved
Lebrikizumab
Lebrikizumab is a monoclonal antibody against IL-13 that binds to a different epitope compared tralokinumab.[A262874,A262879]
On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 years and older with a body weight...
Approved
Investigational
Matched Description: … atopic dermatitis in adult and adolescent patients 12 years and older with a body weight of at least 40 …
Displaying drugs 451 - 475 of 2344 in total